Ergoteles LLC Mirati Therapeutics, Inc. Transaction History

Ergoteles LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $168,028 - $244,840	2,824 Added 52.05%	8,250 $576,000
Q2 2022 Aug 12, 2022	BUY	$39.16 - $88.71 $38,611 - $87,468	986 Added 22.21%	5,426 $364,000
Q1 2022 May 13, 2022	SELL	$75.82 - $150.97 $787,845 - $1.57 Million	-10,391 Reduced 70.06%	4,440 $365,000
Q4 2021 Feb 14, 2022	SELL	$132.01 - $190.29 $6.74 Million - $9.71 Million	-51,031 Reduced 77.48%	14,831 $2.18 Million
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $5.83 Million - $7.83 Million	-44,138 Reduced 40.13%	65,862 $11.7 Million
Q2 2021 Aug 12, 2021	BUY	$144.0 - $179.73 $14.1 Million - $17.6 Million	97,800 Added 801.64%	110,000 $17.8 Million
Q1 2021 May 12, 2021	BUY	$158.92 - $221.61 $1.94 Million - $2.7 Million	12,200 New	12,200 $2.09 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.